Skip to content
Menu

Lucid Diagnostics Inc. LUCD

Full chart Compare
Set alert

Price alert · LUCD

All alert types
0.39 USD -0.02 (-5.25%)

Regular-session close

0.39 0.00 +0.44%

Pre-market · Nov 20, 4:01 AM ET

0.374 Day range 0.4015
0.303 52-week range 1.63
YTD
-64.56%
1 year
-62.13%

5D -0.0446 (-10.43%)

0.40000.45000.5000FriMonTueWedThu0.3830
Market cap
75.22M
Revenue (ttm)
4.19M
EPS (ttm)
-0.35
Shares out
59.34M
Forward P/E
-1.12
YTD return
-64.56%
1-year return
-62.13%
50-day average
0.90474
Volume
1.33M
Avg volume
5.12M
Open
0.40
Previous close
0.4077
Day's range
0.374 – 0.4015
52-week range
0.303 – 1.63
Analysts
Strong Buy
Price target
3.50 (+806.0%)

Key statistics

200-day average
0.87091
Enterprise value
94.79M
Price / sales
10.98
Revenue growth
49.70%
Free cash flow
-39.47M
Total cash
14.49M
Total debt
13.07M
Return on equity
-1007.83%
Short % of float
1.74%

Fundamental scorecard

7 of 25 checks passed on LUCD’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LUCD Revenue — quarterly 1.20M
LUCD Net income — quarterly -6.68M
LUCD EPS — quarterly -0.03

Earnings

LUCD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.16-0.20-0.04-25.00%
Aug 12, 2024Jun 1, 20240.00———
Aug 12, 2024Jun 1, 20240.00-0.20——
May 13, 2024Mar 1, 20240.00-0.21——
May 13, 2024Mar 1, 20240.00———
Mar 25, 2024Dec 1, 20230.00———

Upgrades / downgrades

LUCD analyst upgrades and downgrades
DateFirmActionFromTo
Dec 9, 2024Ascendiant CapitalmainBuyBuy
Nov 15, 2024Cantor FitzgeraldmainOverweightOverweight
Nov 14, 2024Canaccord GenuitymainBuyBuy
Nov 14, 2024NeedhamreitBuyBuy
Sep 10, 2024Ascendiant CapitalmainBuyBuy
Aug 13, 2024Canaccord GenuitymainBuyBuy

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
luciddx.com

News

Your note

Sign in to keep a note on LUCD — it syncs with the Stock Master app.

Insider holders

LUCD insider holders
InsiderRelationLatest transactionDateShares held
AKLOG LISHANChief Executive OfficerStock Award(Grant)May 6, 20241,166,630
GORDON MICHAEL ADAMGeneral CounselStock Award(Grant)May 6, 2024400,000
LAPIDUS STANLEY NDirectorSaleSep 25, 2023101,592
MCGRATH DENNIS MChief Financial OfficerStock Award(Grant)May 6, 20241,043,570
O'NEIL SHAUNPresidentStock Award(Grant)May 6, 2024526,763

Institution ownership

LUCD institution ownership
Holder% heldSharesValueReported
Luminus Management, LLC1.94%1,152,915893.62KSep 29, 2024
Vanguard Group Inc0.95%560,915434.76KSep 29, 2024
Geode Capital Management, LLC0.36%213,540165.51KSep 29, 2024
Nantahala Capital Management, LLC0.21%126,36297.94KSep 29, 2024
Lido Advisors, LLC0.17%100,01677.52KSep 29, 2024
Levin Capital Strategies, LP0.11%66,52851.56KSep 29, 2024

Fund ownership

LUCD fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.62%366,924284.40KSep 29, 2024
Vanguard Extended Market Index Fund0.33%193,991150.36KSep 29, 2024
Fidelity Extended Market Index Fund0.17%101,55678.72KOct 30, 2024
Fidelity Total Market Index Fund0.10%56,57143.85KOct 30, 2024
Fidelity Series Total Market Index Fund0.04%23,99718.60KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%12,8739.98KOct 30, 2024